The journey of a pharmaceutical drug from concept to patient involves numerous chemical transformations, with pharmaceutical intermediates forming the critical backbone of this process. Clidinium Bromide, identified by its CAS Number 3485-62-9, stands out as a significant intermediate in this field. This article delves into the chemical properties, physical form, and crucial applications of Clidinium Bromide within the pharmaceutical sector.

As a white crystalline solid, Clidinium Bromide offers a distinct physical profile that is easily recognizable. Its molecular formula is C22H26BrNO3, with a molecular weight of 432.35 g/mol. These fundamental chemical data points are vital for researchers and manufacturers engaged in its synthesis and application. The compound is highly valued for its anticholinergic properties, which are central to its therapeutic role in various pharmaceutical preparations. These properties enable it to inhibit the effects of acetylcholine, a neurotransmitter involved in regulating involuntary muscle movements and gland secretions.

The primary application of Clidinium Bromide is as a pharmaceutical raw material in the production of antispasmodic drugs. These medications are frequently prescribed to manage conditions affecting the gastrointestinal system, such as Irritable Bowel Syndrome (IBS) and peptic ulcers. By exerting a calming effect on the smooth muscles of the digestive tract and reducing gastric acid secretion, Clidinium Bromide contributes to the relief of symptoms like pain and cramping.

The chemical synthesis of Clidinium Bromide is a complex process requiring stringent quality control measures to achieve a minimum purity of 97%. This high standard is essential for its use in pharmaceutical manufacturing. For companies involved in the development of treatments for IBS, reliable sourcing of Clidinium Bromide is paramount. The consistent availability and quality of this intermediate are fundamental to ensuring the efficacy and safety of the final drug products that reach patients, underscoring its status as a cornerstone pharmaceutical intermediate.